We are excited to announce that VDC Founder company, BIOARRAY Therapeutics Inc., has gained $600,000 of new funding in the initial closing of the company’s Series A funding. The financing, led by Connecticut Innovations, included participation by the Angel Investor Forum, and Boston Harbor Angels, with additional participation from the City of New Haven/CURE Bioscience grant.
BIOARRAY Therapeutics Inc. is a clinical-stage molecular diagnostics company developing and commercializing RNA-based predictive diagnostics for cancer. The new funding comes shortly after election of experienced life-science angel investor, Henry Kay, to BIOARRAY’s Board of Directors last Fall.
To learn more about BIOARRY, click here